Why use mRNA technology if other influenza vaccines already exist? Existing flu vaccines, whether built around inactivated viruses or recombinant proteins, offer 40-60% protection. With mRNA ones, the Nature article explains, immune responses could be broader, strain selection more accurate, and technology could make it easy to include large numbers of antigens. These features should translate into greater protection, which is particularly useful for the elderly
